Breaking News Instant updates and real-time market news.

GLYC

GlycoMimetics

$2.80 /

-0.1 (-3.45%)

07:13
05/01/20
05/01
07:13
05/01/20
07:13

GlycoMimetics reports Q1 EPS (18c), consensus (30c)

Reports Q1 revenue $9,000 vs. no revenue last year. As of March 31, GlycoMimetics had cash and cash equivalents of $ 154.8M as compared to $158.2M as of December 31, 2019. "During the quarter, patient enrollment continued on track in GlycoMimetics' Phase 3 registration program evaluating uproleselan in relapsed/refractory acute myeloid leukemia (AML) as well as in our collaboration with the National Cancer Institute (NCI) on a multi-center clinical trial evaluating the drug candidate in newly diagnosed patients fit for chemotherapy. Enrollment slowed in April as a result of the COVID-19 pandemic, and we continue to actively monitor the situation. At this time it is too early for us to comment on the potential impact of the pandemic on completion of enrollment in either trial, or the potential impact on cash burn. In addition, we are working closely with Apollomics in the Greater China region to initiate the Apollomics-funded third registration trial for uproleselan," commented Rachel King, CEO.

  • 01

    May

  • 22

    May

GLYC GlycoMimetics
$2.80 /

-0.1 (-3.45%)

02/11/20 Roth Capital
GlycoMimetics termination notice from Pfizer no surprise, says Roth Capital
12/10/19 Roth Capital
GlycoMimetics' uproleselan presentation 'very exciting,' says Roth Capital
11/21/19 Roth Capital
GlycoMimetics price target lowered to $9 from $12 at Roth Capital
11/21/19 Stifel
GlycoMimetics' delayed Phase 3 timeline doesn't impact LT thesis, says Stifel

TODAY'S FREE FLY STORIES

Downgrade
Associated British Foods downgraded to Sell from Neutral at Redburn » 06:17
03/03/21
03/03
06:17
03/03/21
06:17
ASBFY

Associated British Foods

$0.00 /

+ (+0.00%)

Redburn analyst Emily…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ASBFY Associated British Foods
$0.00 /

+ (+0.00%)

05:11 Today Redburn
Associated British Foods downgraded to Sell from Neutral at Redburn
02/26/21 Barclays
Associated British Foods price target raised to 2,700 GBp from 2,600 GBp at Barclays
02/23/21 Grupo Santander
Associated British Foods upgraded to Buy from Hold at Grupo Santander
01/21/21 Berenberg
Associated British Foods price target raised to 2,650 GBp at Berenberg
Hot Stocks
Patterson-UTI reports an average of 69 drilling rigs operating in February » 06:17
03/03/21
03/03
06:17
03/03/21
06:17
PTEN

Patterson-UTI

$7.57 /

-0.305 (-3.87%)

Patterson-UTI reported…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PTEN Patterson-UTI
$7.57 /

-0.305 (-3.87%)

PTEN Patterson-UTI
$7.57 /

-0.305 (-3.87%)

12/15/20 Citi
Patterson-UTI price target raised to $6 from $3 at Citi
11/30/20 Susquehanna
Susquehanna raises targets across Oilfield Services on cyclical rebound
07/16/20 Scotiabank
Patterson-UTI downgraded to Underperform from Sector Perform at Scotiabank
05/28/20 Citi
Patterson-UTI price target raised to $4.50 from $1.90 at Citi
PTEN Patterson-UTI
$7.57 /

-0.305 (-3.87%)

Hot Stocks
U.S. District Court rules in AstraZeneca's favor in Symbicort patent litigation » 06:17
03/03/21
03/03
06:17
03/03/21
06:17
AZN

AstraZeneca

$47.72 /

-0.38 (-0.79%)

, MMM

3M

$177.16 /

+0.78 (+0.44%)

, VTRS

Viatris

$14.28 /

-0.46 (-3.12%)

The company states:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AZN AstraZeneca
$47.72 /

-0.38 (-0.79%)

MMM 3M
$177.16 /

+0.78 (+0.44%)

VTRS Viatris
$14.28 /

-0.46 (-3.12%)

AZN AstraZeneca
$47.72 /

-0.38 (-0.79%)

02/25/21
Fly Intel: Top five analyst upgrades
02/25/21 UBS
AstraZeneca upgraded to Buy from Neutral at UBS
02/04/21 Piper Sandler
Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler
02/01/21 BofA
BofA downgrades Moderna to Underperform, sees shares priced for 'best-case'
MMM 3M
$177.16 /

+0.78 (+0.44%)

02/03/21
Fly Intel: Top five analyst upgrades
02/03/21 Argus
3M upgraded to Buy from Hold at Argus
02/03/21 Argus
3M upgraded to Buy from Hold at Argus
01/27/21 Credit Suisse
3M price target lowered to $197 from $208 at Credit Suisse
VTRS Viatris
$14.28 /

-0.46 (-3.12%)

03/02/21 JPMorgan
Viatris downgraded to Neutral on 'modest' growth at JPMorgan
03/02/21 JPMorgan
Viatris downgraded to Neutral from Overweight at JPMorgan
02/26/21 Wolfe Research
Viatris downgraded to Peer Perform from Outperform at Wolfe Research
02/23/21 Barclays
Viatris price target lowered to $20 from $26 at Barclays
AZN AstraZeneca
$47.72 /

-0.38 (-0.79%)

MMM 3M
$177.16 /

+0.78 (+0.44%)

VTRS Viatris
$14.28 /

-0.46 (-3.12%)

AZN AstraZeneca
$47.72 /

-0.38 (-0.79%)

MMM 3M
$177.16 /

+0.78 (+0.44%)

AZN AstraZeneca
$47.72 /

-0.38 (-0.79%)

MMM 3M
$177.16 /

+0.78 (+0.44%)

AZN AstraZeneca
$47.72 /

-0.38 (-0.79%)

MMM 3M
$177.16 /

+0.78 (+0.44%)

VTRS Viatris
$14.28 /

-0.46 (-3.12%)

Recommendations
Veeva price target raised to $350 from $340 at Piper Sandler » 06:16
03/03/21
03/03
06:16
03/03/21
06:16
VEEV

Veeva

$288.36 /

-5.21 (-1.77%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VEEV Veeva
$288.36 /

-5.21 (-1.77%)

VEEV Veeva
$288.36 /

-5.21 (-1.77%)

02/17/21 KeyBanc
Veeva price target raised to $353 from $332 at KeyBanc
01/13/21 Citi
Elastic price target raised to $190 from $160 at Citi
01/11/21 Piper Sandler
Veeva price target raised to $340 from $310 at Piper Sandler
01/11/21 Piper Sandler
Bill.com price target raised to $140 from $120 at Piper Sandler
VEEV Veeva
$288.36 /

-5.21 (-1.77%)

VEEV Veeva
$288.36 /

-5.21 (-1.77%)

Earnings
AES Corp. backs FY21 adjusted EPS view $1.50-$1.58, consensus $1.56 » 06:15
03/03/21
03/03
06:15
03/03/21
06:15
AES

AES Corp.

$26.82 /

-0.18 (-0.67%)

Sees FY21 parent free…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AES AES Corp.
$26.82 /

-0.18 (-0.67%)

AES AES Corp.
$26.82 /

-0.18 (-0.67%)

01/11/21 BofA
BofA US 1 List changes
09/18/20 Morgan Stanley
AES Corp. price target raised to $23.50 from $19 at Morgan Stanley
08/13/20 BofA
AES Corp. added to US 1 List; Ameren removed at BofA
05/20/20 Seaport Global
Seaport Global starts power and competitive retail sector with positive outlook
AES AES Corp.
$26.82 /

-0.18 (-0.67%)

AES AES Corp.
$26.82 /

-0.18 (-0.67%)

Recommendations
ChampionX price target raised to $18 from $12.25 at Piper Sandler » 06:15
03/03/21
03/03
06:15
03/03/21
06:15
CHX

ChampionX

$21.86 /

-0.94 (-4.12%)

Piper Sandler analyst Ian…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CHX ChampionX
$21.86 /

-0.94 (-4.12%)

CHX ChampionX
$21.86 /

-0.94 (-4.12%)

02/26/21 Barclays
ChampionX price target raised to $29 from $23 at Barclays
02/25/21 Wells Fargo
ChampionX price target raised to $24 from $19 at Wells Fargo
01/11/21 Barclays
ChampionX price target raised to EUR 23 from EUR 19 at Barclays
12/21/20 Goldman Sachs
ChampionX initiated with a Buy at Goldman Sachs
CHX ChampionX
$21.86 /

-0.94 (-4.12%)

Recommendations
Adidas price target lowered to EUR 284 from EUR 292 at Piper Sandler » 06:14
03/03/21
03/03
06:14
03/03/21
06:14
ADDYY

Adidas

$0.00 /

+ (+0.00%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ADDYY Adidas
$0.00 /

+ (+0.00%)

ADDYY Adidas
$0.00 /

+ (+0.00%)

02/26/21 RBC Capital
Adidas price target raised to EUR 300 from EUR 290 at RBC Capital
02/23/21 Credit Suisse
Adidas upgraded to Neutral from Underperform at Credit Suisse
02/11/21 UBS
Adidas upgraded to Buy from Neutral at UBS
02/01/21 Deutsche Bank
Adidas price target raised to EUR 250 from EUR 240 at Deutsche Bank
ADDYY Adidas
$0.00 /

+ (+0.00%)

ADDYY Adidas
$0.00 /

+ (+0.00%)

Periodicals
Some Catholic bishops advise against certain Covid-19 vaccines, WSJ reports » 06:14
03/03/21
03/03
06:14
03/03/21
06:14
JNJ

Johnson & Johnson

$159.01 /

-0.32 (-0.20%)

, MRNA

Moderna

$146.61 /

-10.81 (-6.87%)

, PFE

Pfizer

$33.51 /

-0.185 (-0.55%)

At least two Catholic…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
JNJ Johnson & Johnson
$159.01 /

-0.32 (-0.20%)

MRNA Moderna
$146.61 /

-10.81 (-6.87%)

PFE Pfizer
$33.51 /

-0.185 (-0.55%)

JNJ Johnson & Johnson
$159.01 /

-0.32 (-0.20%)

02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
02/01/21 BofA
BofA downgrades Moderna to Underperform, sees shares priced for 'best-case'
MRNA Moderna
$146.61 /

-10.81 (-6.87%)

03/01/21 Chardan
Moderna price target raised to $182 from $107 at Chardan
02/26/21 Barclays
Moderna price target raised to $178 from $169 at Barclays
02/26/21 Brookline
Moderna price target raised to $205 from $180 at Brookline
02/25/21 Piper Sandler
Moderna transitioning into profitable company, says Piper Sandler
PFE Pfizer
$33.51 /

-0.185 (-0.55%)

02/23/21 B. Riley Securities
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
02/03/21 Mizuho
Pfizer price target lowered to $42 from $44 at Mizuho
JNJ Johnson & Johnson
$159.01 /

-0.32 (-0.20%)

MRNA Moderna
$146.61 /

-10.81 (-6.87%)

PFE Pfizer
$33.51 /

-0.185 (-0.55%)

  • 19
    May
JNJ Johnson & Johnson
$159.01 /

-0.32 (-0.20%)

MRNA Moderna
$146.61 /

-10.81 (-6.87%)

PFE Pfizer
$33.51 /

-0.185 (-0.55%)

JNJ Johnson & Johnson
$159.01 /

-0.32 (-0.20%)

MRNA Moderna
$146.61 /

-10.81 (-6.87%)

PFE Pfizer
$33.51 /

-0.185 (-0.55%)

JNJ Johnson & Johnson
$159.01 /

-0.32 (-0.20%)

MRNA Moderna
$146.61 /

-10.81 (-6.87%)

PFE Pfizer
$33.51 /

-0.185 (-0.55%)

Recommendations
I-MAB price target raised to $75 from $55 at H.C. Wainwright » 06:12
03/03/21
03/03
06:12
03/03/21
06:12
IMAB

I-MAB

$59.12 /

-4.98 (-7.77%)

H.C. Wainwright analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IMAB I-MAB
$59.12 /

-4.98 (-7.77%)

IMAB I-MAB
$59.12 /

-4.98 (-7.77%)

02/25/21
Fly Intel: Top five analyst initiations
02/25/21 Piper Sandler
I-MAB initiated with an Overweight at Piper Sandler
12/07/20 H.C. Wainwright
I-MAB initiated with a Buy at H.C. Wainwright
09/08/20 Cantor Fitzgerald
I-MAB price target raised to $55 from $50 at Cantor Fitzgerald
  • 09
    Feb
  • 13
    Jan
IMAB I-MAB
$59.12 /

-4.98 (-7.77%)

Periodicals
Apple could launch foldable iPhone as soon as 2023, Business Insider reports » 06:12
03/03/21
03/03
06:12
03/03/21
06:12
AAPL

Apple

$125.17 /

-2.6 (-2.03%)

A foldable iPhone could…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AAPL Apple
$125.17 /

-2.6 (-2.03%)

AAPL Apple
$125.17 /

-2.6 (-2.03%)

03/01/21 Wedbush
Asia checks bullish for Apple iPhone 12 builds, says Wedbush
03/01/21 JPMorgan
Broadcom won new new wireless charging chipset in iPhone 13, says JPMorgan
02/25/21 JPMorgan
JPMorgan 'tweaks' EPS estimate for Apple after cut to iPhone forecasts
02/24/21 Piper Sandler
Piper sees Apple developing 'full-blown' branded electric vehicle
AAPL Apple
$125.17 /

-2.6 (-2.03%)

AAPL Apple
$125.17 /

-2.6 (-2.03%)

AAPL Apple
$125.17 /

-2.6 (-2.03%)

AAPL Apple
$125.17 /

-2.6 (-2.03%)

Hot Stocks
Dycom announces new $150M share repurchase plan » 06:11
03/03/21
03/03
06:11
03/03/21
06:11
DY

Dycom

$77.36 /

-3.6 (-4.45%)

Dycom announced that its…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DY Dycom
$77.36 /

-3.6 (-4.45%)

DY Dycom
$77.36 /

-3.6 (-4.45%)

01/27/21 KeyBanc
Dycom upgraded to Overweight at KeyBanc
01/27/21 KeyBanc
Dycom upgraded to Overweight from Sector Weight at KeyBanc
01/07/21 B. Riley Securities
Dycom price target raised to $97 from $92 at B. Riley Securities
11/25/20 DA Davidson
Dycom price target raised to $80 from $60 at DA Davidson
DY Dycom
$77.36 /

-3.6 (-4.45%)

Recommendations
Amyris price target raised to $35 from $11 at H.C. Wainwright » 06:11
03/03/21
03/03
06:11
03/03/21
06:11
AMRS

Amyris

$19.91 /

+4.29 (+27.46%)

H.C. Wainwright analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMRS Amyris
$19.91 /

+4.29 (+27.46%)

AMRS Amyris
$19.91 /

+4.29 (+27.46%)

02/26/21
Fly Intel: Top five analyst initiations
02/26/21 Roth Capital
Amyris initiated with a Buy at Roth Capital
01/06/21 Cowen
Amyris upgraded to Outperform with $9 price target at Cowen
01/06/21 Cowen
Amyris upgraded to Outperform from Market Perform at Cowen
AMRS Amyris
$19.91 /

+4.29 (+27.46%)

AMRS Amyris
$19.91 /

+4.29 (+27.46%)

AMRS Amyris
$19.91 /

+4.29 (+27.46%)

Hot Stocks
Mack-Cali Realty names Mahbod Nia CEO » 06:10
03/03/21
03/03
06:10
03/03/21
06:10
CLI

Mack-Cali Realty

$14.24 /

+0.11 (+0.78%)

, NRE

Northstar Realty Europe

$17.02 /

+ (+0.00%)

Mack-Cali Realty (CLI)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CLI Mack-Cali Realty
$14.24 /

+0.11 (+0.78%)

CLI Mack-Cali Realty
$14.24 /

+0.11 (+0.78%)

12/10/20 Citi
Citi opens '90-day negative Catalyst Watch' on Mack-Cali Realty
08/04/20
Fly Intel: Top five analyst downgrades
08/04/20 Deutsche Bank
Mack-Cali Realty downgraded to Hold from Buy at Deutsche Bank
07/20/20 Deutsche Bank
Mack-Cali Realty price target lowered to $20 from $22 at Deutsche Bank
NRE Northstar Realty Europe
$17.02 /

+ (+0.00%)

CLI Mack-Cali Realty
$14.24 /

+0.11 (+0.78%)

Downgrade
Kopin downgraded to Neutral from Buy at H.C. Wainwright » 06:09
03/03/21
03/03
06:09
03/03/21
06:09
KOPN

Kopin

$9.92 /

+0.78 (+8.53%)

H.C. Wainwright analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
KOPN Kopin
$9.92 /

+0.78 (+8.53%)

KOPN Kopin
$9.92 /

+0.78 (+8.53%)

01/11/21 H.C. Wainwright
Kopin price target raised to $3.50 from $2 at H.C. Wainwright
08/25/20
Fly Intel: Top five analyst initiations
08/25/20 H.C. Wainwright
Kopin initiated with a Buy at H.C. Wainwright
08/05/20 Ladenburg
Kopin price target raised to $2.50 from $1.50 at Ladenburg
KOPN Kopin
$9.92 /

+0.78 (+8.53%)

KOPN Kopin
$9.92 /

+0.78 (+8.53%)

Periodicals
JPMorgan looks to sublet office space at two NYC towers, Bloomberg reports » 06:08
03/03/21
03/03
06:08
03/03/21
06:08
JPM

JPMorgan

$150.01 /

-0.4698 (-0.31%)

JPMorgan Chase is looking…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
JPM JPMorgan
$150.01 /

-0.4698 (-0.31%)

JPM JPMorgan
$150.01 /

-0.4698 (-0.31%)

01/19/21 DA Davidson
JPMorgan price target raised to $163 from $147 at DA Davidson
01/19/21 Seaport Global
JPMorgan price target raised to $157 from $140 at Seaport Global
01/19/21 RBC Capital
JPMorgan price target raised to $150 from $130 at RBC Capital
01/19/21 Credit Suisse
JPMorgan price target raised to $150 from $142 at Credit Suisse
JPM JPMorgan
$150.01 /

-0.4698 (-0.31%)

JPM JPMorgan
$150.01 /

-0.4698 (-0.31%)

JPM JPMorgan
$150.01 /

-0.4698 (-0.31%)

Upgrade
Farmers National Banc upgraded to Overweight from Neutral at Piper Sandler » 06:07
03/03/21
03/03
06:07
03/03/21
06:07
FMNB

Farmers National Banc

$14.34 /

+0.065 (+0.46%)

Piper Sandler analyst R.…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FMNB Farmers National Banc
$14.34 /

+0.065 (+0.46%)

09/24/20 Boenning & Scattergood
Farmers National Banc resumed with an Outperform at Boenning & Scattergood
06/17/20 Raymond James
Farmers National Banc upgraded to Outperform from Market Perform at Raymond James
06/17/20 Raymond James
Farmers National Banc upgraded to Outperform from Market Perform at Raymond James
05/04/20 Raymond James
Farmers National Banc downgraded at Raymond James on valuation
FMNB Farmers National Banc
$14.34 /

+0.065 (+0.46%)

Downgrade
KeyCorp downgraded to Neutral from Overweight at Piper Sandler » 06:06
03/03/21
03/03
06:06
03/03/21
06:06
KEY

KeyCorp

$20.65 /

-0.09 (-0.43%)

Piper Sandler analyst R.…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KEY KeyCorp
$20.65 /

-0.09 (-0.43%)

KEY KeyCorp
$20.65 /

-0.09 (-0.43%)

02/17/21 Citi
Citi recommends two new U.S. bank pair trades
01/06/21 Deutsche Bank
KeyCorp price target raised to $18 from $14 at Deutsche Bank
01/04/21 Barclays
KeyCorp price target raised to $20 from $15 at Barclays
10/26/20
Fly Intel: Top five analyst downgrades
KEY KeyCorp
$20.65 /

-0.09 (-0.43%)

KEY KeyCorp
$20.65 /

-0.09 (-0.43%)

KEY KeyCorp
$20.65 /

-0.09 (-0.43%)

Downgrade
First Financial Bancorp downgraded to Neutral from Overweight at Piper Sandler » 06:06
03/03/21
03/03
06:06
03/03/21
06:06
FFBC

First Financial Bancorp

$22.73 /

-0.21 (-0.92%)

Piper Sandler analyst R.…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FFBC First Financial Bancorp
$22.73 /

-0.21 (-0.92%)

FFBC First Financial Bancorp
$22.73 /

-0.21 (-0.92%)

02/01/21 Piper Sandler
First Financial Bancorp upgraded to Overweight from Neutral at Piper Sandler
FFBC First Financial Bancorp
$22.73 /

-0.21 (-0.92%)

FFBC First Financial Bancorp
$22.73 /

-0.21 (-0.92%)

Earnings
Dycom sees Q1 revenue in-line to modestly lower than Q4, consensus $786.14M » 06:06
03/03/21
03/03
06:06
03/03/21
06:06
DY

Dycom

$77.36 /

-3.6 (-4.45%)

Sees Q1 adjusted EBITDA…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DY Dycom
$77.36 /

-3.6 (-4.45%)

DY Dycom
$77.36 /

-3.6 (-4.45%)

01/27/21 KeyBanc
Dycom upgraded to Overweight at KeyBanc
01/27/21 KeyBanc
Dycom upgraded to Overweight from Sector Weight at KeyBanc
01/07/21 B. Riley Securities
Dycom price target raised to $97 from $92 at B. Riley Securities
11/25/20 DA Davidson
Dycom price target raised to $80 from $60 at DA Davidson
DY Dycom
$77.36 /

-3.6 (-4.45%)

Earnings
National Vision sees FY21 adjusted EPS 88c-93c, consensus 88c » 06:04
03/03/21
03/03
06:04
03/03/21
06:04
EYE

National Vision

$47.60 /

-1.79 (-3.62%)

Sees FY21 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
EYE National Vision
$47.60 /

-1.79 (-3.62%)

01/11/21 Loop Capital
National Vision downgraded to Hold from Buy at Loop Capital on valuation
01/11/21 Loop Capital
National Vision downgraded to Hold from Buy at Loop Capital
01/11/21 Loop Capital
National Vision downgraded to Hold from Buy at Loop Capital
11/18/20 Berenberg
National Vision downgraded to Hold from Buy at Berenberg
EYE National Vision
$47.60 /

-1.79 (-3.62%)

EYE National Vision
$47.60 /

-1.79 (-3.62%)

Earnings
Dycom reports Q4 EPS (7c), consensus 4c » 06:04
03/03/21
03/03
06:04
03/03/21
06:04
DY

Dycom

$77.36 /

-3.6 (-4.45%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DY Dycom
$77.36 /

-3.6 (-4.45%)

DY Dycom
$77.36 /

-3.6 (-4.45%)

01/27/21 KeyBanc
Dycom upgraded to Overweight at KeyBanc
01/27/21 KeyBanc
Dycom upgraded to Overweight from Sector Weight at KeyBanc
01/07/21 B. Riley Securities
Dycom price target raised to $97 from $92 at B. Riley Securities
11/25/20 DA Davidson
Dycom price target raised to $80 from $60 at DA Davidson
DY Dycom
$77.36 /

-3.6 (-4.45%)

Upgrade
Rapid7 upgraded to Overweight with $100 target at Piper Sandler » 06:04
03/03/21
03/03
06:04
03/03/21
06:04
RPD

Rapid7

$79.21 /

-2.07 (-2.55%)

Piper Sandler analyst Rob…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
RPD Rapid7
$79.21 /

-2.07 (-2.55%)

RPD Rapid7
$79.21 /

-2.07 (-2.55%)

03/02/21 Piper Sandler
Rapid7 upgraded to Overweight from Neutral at Piper Sandler
02/17/21 Stifel
Rapid7 resumed with a Buy at Stifel
02/10/21 Morgan Stanley
Morgan Stanley downgrades Qualys to Underweight on growth and margin pressures
02/10/21 RBC Capital
Rapid7 price target raised to $110 from $105 at RBC Capital
RPD Rapid7
$79.21 /

-2.07 (-2.55%)

RPD Rapid7
$79.21 /

-2.07 (-2.55%)

Earnings
National Vision reports Q4 adjusted EPS 45c, consensus 13c » 06:02
03/03/21
03/03
06:02
03/03/21
06:02
EYE

National Vision

$47.60 /

-1.79 (-3.62%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EYE National Vision
$47.60 /

-1.79 (-3.62%)

01/11/21 Loop Capital
National Vision downgraded to Hold from Buy at Loop Capital on valuation
01/11/21 Loop Capital
National Vision downgraded to Hold from Buy at Loop Capital
01/11/21 Loop Capital
National Vision downgraded to Hold from Buy at Loop Capital
11/18/20 Berenberg
National Vision downgraded to Hold from Buy at Berenberg
EYE National Vision
$47.60 /

-1.79 (-3.62%)

EYE National Vision
$47.60 /

-1.79 (-3.62%)

Upgrade
CIBC upgraded to Neutral from Underperform at Credit Suisse » 06:02
03/03/21
03/03
06:02
03/03/21
06:02
CM

CIBC

$94.91 /

+1.43 (+1.53%)

Credit Suisse analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CM CIBC
$94.91 /

+1.43 (+1.53%)

CM CIBC
$94.91 /

+1.43 (+1.53%)

03/01/21 Desjardins
CIBC price target raised to C$122 from C$117 at Desjardins
02/26/21 Canaccord
CIBC price target raised to C$131 from C$124.50 at Canaccord
02/26/21 RBC Capital
CIBC price target raised to C$141 from C$130 at RBC Capital
02/26/21 National Bank
CIBC price target raised to C$130 from C$126 at National Bank
CM CIBC
$94.91 /

+1.43 (+1.53%)

Hot Stocks
CMC Materials raises quarterly dividend to 46c, raises share repurchase to $150M » 06:02
03/03/21
03/03
06:02
03/03/21
06:02
CCMP

CMC Materials

$168.26 /

-8.41 (-4.76%)

CMC Materials announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CCMP CMC Materials
$168.26 /

-8.41 (-4.76%)

CCMP CMC Materials
$168.26 /

-8.41 (-4.76%)

01/25/21 Citi
Citi moves Marvell up to pick in semiconductor equipment
01/25/21 Citi
CMC Materials price target raised to $150 from $140 at Citi
01/18/21 Goldman Sachs
CMC Materials upgraded to Neutral from Sell at Goldman Sachs
11/13/20
Fly Intel: Top five analyst downgrades
CCMP CMC Materials
$168.26 /

-8.41 (-4.76%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.